Cbz-L-Orn(N3)-OH | 1001646-61-2

• 分子结构分类: 有机化合物 - 苯类化合物 - 苯和取代衍生物
• 英文名称: Cbz-L-Orn(N3)-OH
• 英文别名: 5-azido-2-(((benzyloxy)carbonyl)amino)pentanoic acid；(S)-5-azido-2-(((benzyloxy)carbonyl)amino)pentanoic acid；(2S)-5-azido-2-{[(benzyloxy)carbonyl]amino}pentanoic acid；(2S)-5-azido-2-(phenylmethoxycarbonylamino)pentanoic acid
• CAS: 1001646-61-2
• 化学式: C₁₃H₁₆N₄O₄
• 分子量: 292.294
• InChiKey: ZVLVODXLXCLCPR-NSHDSACASA-N

计算性质

• 辛醇/水分配系数(LogP)：
  2.7
• 重原子数：
  21
• 可旋转键数：
  9
• 环数：
  1.0
• sp3杂化的碳原子比例：
  0.38
• 拓扑面积：
  90
• 氢给体数：
  2
• 氢受体数：
  6

反应信息

• 作为反应物：
  描述：

  Cbz-L-Orn(N3)-OH 在 1-羟基苯并三唑 、 盐酸-N-乙基-Nˊ-(3-二甲氨基丙基)碳二亚胺 、 N,N-二异丙基乙胺 、 三氟乙酸 作用下， 以 二氯甲烷 为溶剂， 反应 4.0h， 生成 (S)-2-((S)-5-azido-2-(((benzyloxy)carbonyl)amino)pentanamido)-4-methylpentanoic acid
  参考文献：
  名称：

  New β-Strand Templates Constrained by Huisgen Cycloaddition

  摘要：

  New peptidic templates constrained into a beta-strand geometry by linking acetylene and azide containing P-1 and P-3 residues of a tripeptide by Huisgen cycloaddition are presented. The conformations of the macrocycles are defined by NMR studies and those that best define a beta-strand are shown to be potent inhibitors of the protease calpain. The beta-strand templates presented and defined here are prepared under optimized conditions that should be suitable for targeting a range of proteases and other applications requiring such a geometry.

  DOI：

  10.1021/ol3002199
• 作为产物：
  描述：

  methyl (S)-5-azido-2-(((benzyloxy)carbonyl)amino)pentanoate 在 potassium hydrogencarbonate 作用下， 以 叔丁醇 为溶剂， 反应 0.08h， 生成 Cbz-L-Orn(N3)-OH
  参考文献：
  名称：

  Chemoenzymatic Synthesis of Triazole-Linked Glycopeptides

  摘要：

  三氮唑联接的糖肽通过糖氨基酸的C端延伸，与蛋白质氨基酸按照化学或酶促耦合协议制备。探索了两条正交路径的化学酶促策略，涉及在酰胺键形成之前或顺序相反的点击反应。研究发现，在碱性蛋白酶的影响下，酶促肽耦合过程顺利进行且产率较高，同时所得的二肽可以高效地与含有炔烃或叠氮的糖发生点击反应。

  DOI：

  10.1055/s-2006-942509

文献信息

• Structure-based design and synthesis of triazole-based macrocyclic inhibitors of norovirus protease: Structural, biochemical, spectroscopic, and antiviral studies
  作者：Pathum M. Weerawarna、Yunjeong Kim、Anushka C. Galasiti Kankanamalage、Vishnu C. Damalanka、Gerald H. Lushington、Kevin R. Alliston、Nurjahan Mehzabeen、Kevin P. Battaile、Scott Lovell、Kyeong-Ok Chang、William C. Groutas

  DOI：10.1016/j.ejmech.2016.04.013

  日期：2016.8

  effective strategy for the development of norovirus therapeutics entails the discovery of inhibitors of norovirus 3CL protease, an enzyme essential for noroviral replication. We describe herein the structure-based design of the first class of permeable, triazole-based macrocyclic inhibitors of norovirus 3C-like protease, as well as pertinent X-ray crystallographic, biochemical, spectroscopic, and antiviral

  由诺如病毒引起的急性肠胃炎暴发构成了全世界的公共卫生问题。迄今为止，尚无获批用于管理和预防诺如病毒感染的药物或疫苗。开发诺如病毒疗法的潜在有效策略需要发现诺如病毒 3CL 蛋白酶的抑制剂，这是一种对诺如病毒复制至关重要的酶。我们在此描述了基于结构的第一类诺如病毒 3C 样蛋白酶的可渗透、三唑基大环抑制剂的设计，以及相关的 X 射线晶体学、生化、光谱和抗病毒研究。
• [EN] ANTIFOLATE LINKER-DRUGS AND ANTIBODY-DRUG CONJUGATES<br/>[FR] MÉDICAMENTS LIEURS D'ANTIFOLATE ET CONJUGUÉS ANTICORPS-MÉDICAMENT
  申请人：BYONDIS BV

  公开号：WO2022008419A1

  公开（公告）日：2022-01-13

  The present invention relates to novel antifolate linker-drugs, conjugates comprising such antifolate linker-drugs, and the use thereof in the treatment of diseases, such as cancer, autoimmune and infectious diseases, optionally in combination with other therapeutic agents.

  本发明涉及新型抗叶酸连接剂药物，包括这种抗叶酸连接剂的共轭物，并将其用于治疗疾病，如癌症、自身免疫和传染病，可选择性地与其他治疗剂联合使用。
• Compounds and Compositions as Channel Activating Protease Inhibitors
  申请人：Tully C. David

  公开号：US20070275906A1

  公开（公告）日：2007-11-29

  The invention provides compounds and pharmaceutical compositions thereof, which are useful for modulating channel activating proteases, and methods for, using such compounds to treat, ameliorate or prevent a condition associated with a channel activating protease, including but not limited to prostasin, PRSS22, TMPRSS11 (e.g., TMPRSS11B, TMPRSS11E), TMPRSS2, TMPRSS3, TMPRSS4 (MTSP-2), matriptase (MTSP-1), CAP2, CAP3, trypsin, cathepsin A, or neutrophil elastase.

  该发明提供了化合物及其制药组合物，用于调节通道激活蛋白酶，并使用这些化合物来治疗、改善或预防与通道激活蛋白酶相关的疾病的方法，包括但不限于前列腺蛋白酶、PRSS22、TMPRSS11（例如TMPRSS11B、TMPRSS11E）、TMPRSS2、TMPRSS3、TMPRSS4（MTSP-2）、麦曲蛋白酶（MTSP-1）、CAP2、CAP3、胰蛋白酶、卡特普辛A或中性粒细胞弹性蛋白酶。
• Cu-Catalyzed Formation of Triazole-Linked Glycoamino Acids and Application in Chemoenzymatic Peptide Synthesis
  作者：Brian H. M. Kuijpers、Stan Groothuys、Christine Hawner、Jeroen ten Dam、Peter J. L. M. Quaedflieg、Hans E. Schoemaker、Floris L. van Delft、Floris P. J. T. Rutjes

  DOI：10.1021/op700249f

  日期：2008.5.1

  Novel stable triazole-linked glycoamino acids have been prepared, with the heterocyclic moiety being established by efficient Cu-mediated cycloaddition between the corresponding azido and acetylene moieties. Selected reactions were scaled up and successfully subjected to chemoenzymatic peptide-coupling reactions involving the proteolytic enzyme alcalase, resulting in several glycosylated di- and tripeptide structures. Since chemoenzymatic approaches have several advantages over chemical peptide coupling, especially concerning large-scale peptide synthesis, these results may be regarded as initial steps in the direction of production via fully chemoenzymatic peptide synthesis.
• COMPOUNDS AND COMPOSITIONS AS CHANNEL ACTIVATING PROTEASE INHIBITORS
  申请人：Tully David C.

  公开号：US20110257077A1

  公开（公告）日：2011-10-20

  The invention provides compounds and pharmaceutical compositions thereof, which are useful for modulating channel activating proteases, and methods for, using such compounds to treat, ameliorate or prevent a condition associated with a channel activating protease, including but not limited to prostasin, PRSS22, TMPRSS11 (e.g., TMPRSS11B, TMPRSS11E), TMPRSS2, TMPRSS3, TMPRSS4 (MTSP-2), matriptase (MTSP-1), CAP2, CAP3, trypsin, cathepsin A, or neutrophil elastase.